Stada plans a billion-dollar exchange: Chance for the future!

Stada plans a billion-dollar exchange: Chance for the future!

The pharmaceutical company Stada plans a billion dollar IPO, which is expected to take place around Easter 2025 on the Frankfurt Stock Exchange. With this measure, Stada, known for products such as Grippostad and Silomat, would like to take between one and two billion euros in order to reduce the debt burden. Stada's net debt, which has arisen from years of acquisitions and expansions, amounts to 5.5 billion euros. In recent years, the company has made around 20 larger takeover worth 1.6 billion euros to strengthen its market position.

Andreas Fibig, a former manager of Bayer, will probably work as an independent chairman of the board. He is currently a member of the board at Novo Nordisk and was previously boss at International Flavor & Fragrances and Bayer Health Care Pharmaceuticals. Peter Goldschmidt will continue to act as a global CEO of Stada. The newly founded listed corporate holding company is founded under Dutch law, but is based in Germany. The exact shares that the previous owners want to hand in Bain Capital and Cinven are still unknown. Bain Capital and Cinven bought Stada in 2017 for 5.3 billion euros and then took it off the market.

Financial development and market strategy

Stada increased sales by 14 percent to 3.7 billion euros in 2023. The profit before interest, taxes and depreciation (EBITDA) grew by 19 percent to 802 million euros, whereby the numbers are adjusted to the Russian business. The Russian business, which previously contributed more than 15 percent to turnover, was outsourced to an independent company called Nizhpharm. Analysts expect Stada to climb into the MDAX after the IPO. The Consumer Healthcare area generated sales of 1.46 billion euros in the same year, while sales of special medication and biotech products grew by 25 percent to 749 million euros.

The banks JP Morgan, Morgan Stanley and Rothschild accompany the IPO, which is considered the best opportunity to monetize the investment, despite existing geopolitical risks that could affect the IPO. Originally, a sale to another financial investor was planned, but the negotiations failed.

for more details on this project Black Forest messenger Efficiency and profitability of Stada in recent years significantly contribute to the stability of the company.

In addition, Investment Week that the restructuring of the company and the strategic focus on more profitable areas are decisive for the future of Stada.

-transmitted by West-Ost-Medien